These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19183107)

  • 41. Probing and Enhancing Ligand-Mediated Active Targeting of Tumors Using Sub-5 nm Ultrafine Iron Oxide Nanoparticles.
    Xu Y; Wu H; Huang J; Qian W; Martinson DE; Ji B; Li Y; Wang YA; Yang L; Mao H
    Theranostics; 2020; 10(6):2479-2494. PubMed ID: 32194814
    [No Abstract]   [Full Text] [Related]  

  • 42. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.
    Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
    Mol Cancer Ther; 2006 Dec; 5(12):3170-80. PubMed ID: 17172421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Novel Peptide-Equipped Exosomes Platform for Delivery of Antisense Oligonucleotides.
    Xu H; Liao C; Liang S; Ye BC
    ACS Appl Mater Interfaces; 2021 Mar; 13(9):10760-10767. PubMed ID: 33621039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
    Yang DC; Jiang XP; Elliott RL; Head JF
    Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature.
    Anderson EM; Miller P; Ilsley D; Marshall W; Khvorova A; Stein CA; Benimetskaya L
    Cancer Gene Ther; 2006 Apr; 13(4):406-14. PubMed ID: 16195754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes.
    Weecharangsan W; Yu B; Zheng Y; Liu S; Pang JX; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2009; 6(6):1848-55. PubMed ID: 19725564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
    Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.
    Ko YT; Falcao C; Torchilin VP
    Mol Pharm; 2009; 6(3):971-7. PubMed ID: 19317442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis.
    Buck AC; Shen C; Schirrmeister H; Schmid-Kotsas A; Munzert G; Guhlmann A; Mehrke G; Klug N; Gross HJ; Bachem M; Reske SN
    Cancer Biother Radiopharm; 2002 Jun; 17(3):281-9. PubMed ID: 12136520
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.
    Jiang H; Xia D; Wu LJ; Chen ZD
    Chin Med J (Engl); 2011 Dec; 124(23):4018-21. PubMed ID: 22340335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model.
    Wacheck V; Heere-Ress E; Halaschek-Wiener J; Lucas T; Meyer H; Eichler HG; Jansen B
    J Mol Med (Berl); 2001 Oct; 79(10):587-93. PubMed ID: 11692156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation.
    Zhu B; Zhang H; Yu L
    Biomed Pharmacother; 2017 Feb; 86():547-554. PubMed ID: 28024291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
    Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex.
    Kang T; Jiang M; Jiang D; Feng X; Yao J; Song Q; Chen H; Gao X; Chen J
    Mol Pharm; 2015 Aug; 12(8):2947-61. PubMed ID: 26149889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fattigation-platform nanoparticles using apo-transferrin stearic acid as a core for receptor-oriented cancer targeting.
    Amin HH; Meghani NM; Park C; Nguyen VH; Tran TT; Tran PH; Lee BJ
    Colloids Surf B Biointerfaces; 2017 Nov; 159():571-579. PubMed ID: 28854413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner.
    Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA
    Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
    Lopes de Menezes DE; Hu Y; Mayer LD
    J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells.
    Nag M; Gajbhiye V; Kesharwani P; Jain NK
    Colloids Surf B Biointerfaces; 2016 Dec; 148():363-370. PubMed ID: 27632697
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo.
    Ma Y; Zhao W; Li Y; Pan Y; Wang S; Zhu Y; Kong L; Guan Z; Wang J; Zhang L; Yang Z
    Biomaterials; 2019 Mar; 197():182-193. PubMed ID: 30660994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.